alprazolam has been researched along with Agoraphobia in 113 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compares the speed of onset of action of the extended release (XR) formulation of alprazolam with that of the compressed tablet (CT) formulation in a sample of outpatients with DSM-IV panic disorder." | 9.12 | The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. ( Raj, BA; Sheehan, DV; Sheehan, KH, 2007) |
| " A previous study with agoraphobia/panic patients found that the BZ alprazolam impaired memory during an 8-week treatment and residual impairments were still manifest several weeks after drug withdrawal (Curran et al." | 9.09 | Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients. ( Başoğlu, M; Curran, HV; Kiliç, C; Marks, IM; Noshirvani, H, 1999) |
| ") and to clonidine (150 micrograms) were measured in 10 outpatients with panic disorder before and after 30 days of 2-2." | 9.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. ( Bellodi, L; Brambilla, F; Garberi, A; Nobile, P; Perna, G, 1995) |
| "The cortisol responses to acute administration of saline and of clonidine (Clon), 150 micrograms IV, were examined in 12 patients with panic disorder and agoraphobia, before and after 32 days of alprazolam therapy (2." | 9.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. ( Arancio, C; Bellodi, L; Brambilla, F; Nobile, P; Perna, G, 1995) |
| "23 patients with a diagnosis of panic disorder with agoraphobia were randomly assigned to 8 weeks' treatment with alprazolam or placebo." | 9.08 | Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. ( Bond, AJ; Bruce, MS; Curran, HV; O'Sullivan, G; Shine, P, 1995) |
| "Patients with panic disorder plus agoraphobia had 8 weeks of drug treatment (alprazolam or placebo) plus psychological treatment (exposure or relaxation)." | 9.07 | Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. ( Başoğlu, M; Brewin, CR; Kiliç, C; Marks, IM; Swinson, RP, 1994) |
| " The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured." | 9.07 | Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. ( Başoğlu, M; Kirby, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, GH; Swinson, R, 1994) |
| " Eighty-two agoraphobics with panic disorder were randomly allocated to one of four treatment groups resulting from a combination of two drug treatments (alprazolam or placebo) and two psychological treatments (exposure or relaxation)." | 9.07 | Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. ( Bond, A; Bruce, M; Curran, HV; Lader, M; Lelliot, P; Marks, I; O'Sullivan, G; Shine, P, 1994) |
| "Pre-treatment predictors of treatment outcome were examined in a group of 144 patients with panic disorder and agoraphobia randomly allocated to alprazolam+exposure (AE), placebo+exposure (PE), alprazolam+relaxation (AR), and placebo+relaxation (PR)." | 9.07 | Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "In a controlled trial of alprazolam and exposure in 154 patients with panic disorder with agoraphobia, relations between panic, anticipatory anxiety, and phobic avoidance were examined." | 9.07 | Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kiliç, C; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "A cross-national randomised trial of alprazolam for chronic panic disorder with agoraphobia was run." | 9.07 | Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. ( Başoğlu, M; Kirby, M; Kuch, K; Lelliott, PT; Marks, IM; McNamee, G; Noshirvani, H; O'Sullivan, G; Sengun, S; Swinson, RP, 1993) |
| "A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam." | 9.07 | A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. ( Ballenger, JC; DuPont, R; Laraia, M; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 9.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "Ninety-six patients with panic disorder and agoraphobia were treated at three sites in a 6-week, fixed-dose, double-blind, placebo-controlled, dose-response study of 2 mg/day or 6 mg/day of alprazolam." | 9.07 | Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. ( Antal, E; Ballenger, JC; DuPont, R; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "A series of 237 patients with DSM-III-diagnosed panic disorder, or agoraphobia with panic attacks, received alprazolam as part of the placebo-controlled Cross-National Collaborative Panic Study." | 9.07 | Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. ( Greenblatt, DJ; Harmatz, JS; Shader, RI, 1993) |
| "In a multicenter placebo-controlled study, the safety, side effects, and patient acceptance of alprazolam for the treatment of panic disorder and agoraphobia were examined." | 9.06 | Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. ( Ballenger, JC; Burrows, GD; DuPont, RL; Noyes, R; Pecknold, JC; Rifkin, A; Rubin, RT; Swinson, RP, 1988) |
| "Fifty-five patients completed a 5-week double-blind study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks." | 9.06 | Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. ( Brown, R; Cabe, D; Crocker, B; Leonard, M; McDowell, D; McManus, M; Munjack, DJ; Palmer, R; Usigli, R; Zulueta, A, 1989) |
| "We performed a meta-analysis of all single- or double-blind, randomized controlled trials comparing alprazolam to another benzodiazepine in the treatment of adult patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Third or Fourth Edition, criteria for panic disorder or agoraphobia with panic attacks." | 8.87 | The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. ( Berk, M; Moylan, S; Rogerson, J; Staples, J; Stein, DJ; Ward, SA, 2011) |
| "Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) were measured in 10 outpatients with panic disorder, twice (at a 48-h interval) before and twice on days 30-32 of treatment with alprazolam (2-2." | 7.70 | Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. ( Bellodi, L; Brambilla, F; Perna, G, 1999) |
| "Out of 69 patients with panic disorder plus agoraphobia who had been in an 8-week controlled study of alprazolam and/or exposure, 31 were followed up at a mean of 3." | 7.69 | Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. ( Başoğlu, M; Kiliç, C; Marks, I; Noshirvani, H, 1997) |
| "This study applied the corticotropin-releasing hormone (CRH) stimulation test to patients with panic disorder, before and during treatment with alprazolam, and to control subjects." | 7.69 | Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. ( Abelson, JL; Curtis, GC; Gold, PW, 1997) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 7.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| " The charts of 78 panic disorder outpatients treated with alprazolam (mean dose 4." | 7.68 | Alprazolam in panic disorder: a retrospective analysis. ( Harvey, DS; Loosen, PT; Shelton, RC; Stewart, PM, 1993) |
| "Clonazepam, a high-potency benzodiazepine marketed for the treatment of minor motor epilepsy, was used to treat 50 patients with panic disorder (N = 22) or agoraphobia with panic attacks (N = 28)." | 7.67 | Treatment of panic disorder and agoraphobia with clonazepam. ( Rosenbaum, JF; Spier, SA; Tesar, GE; Woods, SW, 1986) |
| " A decrease in therapeutic effects of alprazolam after an initial good response is described in three patients suffering from panic disorder with agoraphobia." | 7.67 | Fading of therapeutic effects of alprazolam in agoraphobia. Case reports. ( Fava, GA, 1988) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 6.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "Panic disorder is a chronic illness with only some degree of spontaneous recovery." | 6.67 | Discontinuation reactions to alprazolam in panic disorder. ( Pecknold, JC, 1993) |
| "This study compares the speed of onset of action of the extended release (XR) formulation of alprazolam with that of the compressed tablet (CT) formulation in a sample of outpatients with DSM-IV panic disorder." | 5.12 | The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. ( Raj, BA; Sheehan, DV; Sheehan, KH, 2007) |
| " A previous study with agoraphobia/panic patients found that the BZ alprazolam impaired memory during an 8-week treatment and residual impairments were still manifest several weeks after drug withdrawal (Curran et al." | 5.09 | Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients. ( Başoğlu, M; Curran, HV; Kiliç, C; Marks, IM; Noshirvani, H, 1999) |
| "23 patients with a diagnosis of panic disorder with agoraphobia were randomly assigned to 8 weeks' treatment with alprazolam or placebo." | 5.08 | Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. ( Bond, AJ; Bruce, MS; Curran, HV; O'Sullivan, G; Shine, P, 1995) |
| "A group of 20 patients who met the DSM-III-R criteria for panic disorder with or without agoraphobia underwent a 35% carbon dioxide (CO2) challenge after either 1 mg alprazolam or placebo in a double-blind, randomized, cross-over design." | 5.08 | Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. ( Griez, E; Hauzer, R; Meijer, J; Pols, H; Verburg, K, 1996) |
| ") and to clonidine (150 micrograms) were measured in 10 outpatients with panic disorder before and after 30 days of 2-2." | 5.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. ( Bellodi, L; Brambilla, F; Garberi, A; Nobile, P; Perna, G, 1995) |
| "The cortisol responses to acute administration of saline and of clonidine (Clon), 150 micrograms IV, were examined in 12 patients with panic disorder and agoraphobia, before and after 32 days of alprazolam therapy (2." | 5.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. ( Arancio, C; Bellodi, L; Brambilla, F; Nobile, P; Perna, G, 1995) |
| "In 129 patients with panic disorder and agoraphobia who were randomized to alprazolam-exposure, placebo-exposure, alprazolam-relaxation, or placebo-relaxation conditions, blindness was tested at the end of treatment by the independent assessors' and patients' classification of the treatment condition." | 5.08 | Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. ( Başoğlu, M; Livanou, M; Marks, I; Swinson, R, 1997) |
| "Patients with panic disorder plus agoraphobia had 8 weeks of drug treatment (alprazolam or placebo) plus psychological treatment (exposure or relaxation)." | 5.07 | Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. ( Başoğlu, M; Brewin, CR; Kiliç, C; Marks, IM; Swinson, RP, 1994) |
| " The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured." | 5.07 | Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. ( Başoğlu, M; Kirby, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, GH; Swinson, R, 1994) |
| " Eighty-two agoraphobics with panic disorder were randomly allocated to one of four treatment groups resulting from a combination of two drug treatments (alprazolam or placebo) and two psychological treatments (exposure or relaxation)." | 5.07 | Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. ( Bond, A; Bruce, M; Curran, HV; Lader, M; Lelliot, P; Marks, I; O'Sullivan, G; Shine, P, 1994) |
| "Pre-treatment predictors of treatment outcome were examined in a group of 144 patients with panic disorder and agoraphobia randomly allocated to alprazolam+exposure (AE), placebo+exposure (PE), alprazolam+relaxation (AR), and placebo+relaxation (PR)." | 5.07 | Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "In a controlled trial of alprazolam and exposure in 154 patients with panic disorder with agoraphobia, relations between panic, anticipatory anxiety, and phobic avoidance were examined." | 5.07 | Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kiliç, C; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| " The present study provided systematic data from a double blind comparison of maintenance therapy (up to 8 months) of panic disorder with or without agoraphobia with alprazolam, imipramine, or placebo in 181 patients who had responded to the same regimen in a randomized 8-week treatment trial." | 5.07 | Maintenance drug therapy of panic disorder. ( Ayuso, JL; Cassano, GB; Curtis, GC; Massana, J; Perugi, G; Udina, C, 1993) |
| "A cross-national randomised trial of alprazolam for chronic panic disorder with agoraphobia was run." | 5.07 | Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. ( Başoğlu, M; Kirby, M; Kuch, K; Lelliott, PT; Marks, IM; McNamee, G; Noshirvani, H; O'Sullivan, G; Sengun, S; Swinson, RP, 1993) |
| "Ninety-six patients with panic disorder and agoraphobia were treated at three sites in a 6-week, fixed-dose, double-blind, placebo-controlled, dose-response study of 2 mg/day or 6 mg/day of alprazolam." | 5.07 | Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. ( Antal, E; Ballenger, JC; DuPont, R; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "A series of 237 patients with DSM-III-diagnosed panic disorder, or agoraphobia with panic attacks, received alprazolam as part of the placebo-controlled Cross-National Collaborative Panic Study." | 5.07 | Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. ( Greenblatt, DJ; Harmatz, JS; Shader, RI, 1993) |
| "A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam." | 5.07 | A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. ( Ballenger, JC; DuPont, R; Laraia, M; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 5.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "We studied the efficacy of propranolol (Inderal) compared to alprazolam (Xanax) in 29 patients with a diagnosis of agoraphobia with panic disorder or panic disorder with or without limited phobic avoidance in a 6-week double-blind controlled experiment." | 5.07 | A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. ( Friedman, MJ; Hauri, PJ; McHugo, GJ; Ravaris, CL, 1991) |
| "The impact of the avoidance behaviour on the psychopharmacological treatment of panic disorder was explored in the Cross National Collaborative Panic Study (n = 1134 patients); in this double blind randomized trial alprazolam, imipramine and placebo were compared during an 8-week treatment period." | 5.07 | Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? ( Argyle, N; Benkert, O; Brandon, S; Buller, R; Lavori, P; Maier, W; Roth, SM, 1991) |
| "Fifty-five young adult patients completed a study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks." | 5.07 | Alprazolam levels and response in panic disorder: preliminary results. ( Munjack, DJ; Palmer, R; Wincor, MZ, 1991) |
| " A double blind study of alprazolam and placebo in 118 patients with agoraphobia and panic is presented." | 5.06 | Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam. ( Kuch, K; Pecknold, JC; Swinson, RP, 1987) |
| "In a multicenter placebo-controlled study, the safety, side effects, and patient acceptance of alprazolam for the treatment of panic disorder and agoraphobia were examined." | 5.06 | Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. ( Ballenger, JC; Burrows, GD; DuPont, RL; Noyes, R; Pecknold, JC; Rifkin, A; Rubin, RT; Swinson, RP, 1988) |
| "An open clinical trial of alprazolam therapy of patients with panic disorder or agoraphobia with panic attacks was undertaken to clarify certain issues not resolved by previous studies." | 5.06 | Alprazolam in the treatment of panic disorders. ( Campeas, R; Davies, SR; Fyer, AJ; Goetz, D; Gorman, JM; Klein, DF; Levin, A; Liebowitz, MR, 1986) |
| "The antipanic efficacy of alprazolam and lorazepam was evaluated in 48 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder in a double-blind random assignment study." | 5.06 | Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. ( Charney, DS; Woods, SW, 1989) |
| "Fifty-five patients completed a 5-week double-blind study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks." | 5.06 | Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. ( Brown, R; Cabe, D; Crocker, B; Leonard, M; McDowell, D; McManus, M; Munjack, DJ; Palmer, R; Usigli, R; Zulueta, A, 1989) |
| "In a multi-center comparison of alprazolam to placebo in the treatment of agoraphobia with panic attacks, the sequence of sustained remission in both treatment groups, was panic attacks before phobias." | 5.06 | Sequence of improvement in agoraphobia with panic attacks. ( Ballenger, JC; Burrows, GD; Dupont, RL; Lesser, I; Noyes, R; Pecknold, JC; Rifkin, A; Swinson, RP, 1990) |
| "Thirty-two patients with chronic debilitating agoraphobia and panic attacks participated in a comparative study of the triazolobenzodiazepine alprazolam and the anti-inflammatory agent ibuprofen." | 5.05 | Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. ( Coleman, JH; Greenblatt, DJ; Jones, KJ; Levine, PH; Orsulak, PJ; Peterson, M; Schildkraut, JJ; Sheehan, DV; Uzogara, E; Watkins, D, 1984) |
| "Patients who met DSM-III criteria for agoraphobia with panic attacks underwent dexamethasone suppression tests (DSTs) before, during, and after treatment with alprazolam or placebo." | 5.05 | Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks. ( Chaudhry, D; Clancy, J; Coryell, W; Crowe, R; Noyes, R, 1985) |
| "We performed a meta-analysis of all single- or double-blind, randomized controlled trials comparing alprazolam to another benzodiazepine in the treatment of adult patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Third or Fourth Edition, criteria for panic disorder or agoraphobia with panic attacks." | 4.87 | The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. ( Berk, M; Moylan, S; Rogerson, J; Staples, J; Stein, DJ; Ward, SA, 2011) |
| " For panic disorder and agoraphobia with panic, the tricyclic antidepressants, the monoamine oxidase inhibitors, and the atypical benzodiazepine alprazolam have proved effective." | 4.77 | Pharmacotherapeutic considerations in anxiety disorders. ( Hollister, LE, 1986) |
| "Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) were measured in 10 outpatients with panic disorder, twice (at a 48-h interval) before and twice on days 30-32 of treatment with alprazolam (2-2." | 3.70 | Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. ( Bellodi, L; Brambilla, F; Perna, G, 1999) |
| "This study applied the corticotropin-releasing hormone (CRH) stimulation test to patients with panic disorder, before and during treatment with alprazolam, and to control subjects." | 3.69 | Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. ( Abelson, JL; Curtis, GC; Gold, PW, 1997) |
| "Out of 69 patients with panic disorder plus agoraphobia who had been in an 8-week controlled study of alprazolam and/or exposure, 31 were followed up at a mean of 3." | 3.69 | Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. ( Başoğlu, M; Kiliç, C; Marks, I; Noshirvani, H, 1997) |
| " The charts of 78 panic disorder outpatients treated with alprazolam (mean dose 4." | 3.68 | Alprazolam in panic disorder: a retrospective analysis. ( Harvey, DS; Loosen, PT; Shelton, RC; Stewart, PM, 1993) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 3.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| "Immunological, neuroendocrine and psychological parameters were examined in 14 psychophysically healthy subjects and in 17 panic disorder patients before and after a 30-day course of alprazolam therapy." | 3.68 | Psychoimmunoendocrine aspects of panic disorder. ( Battaglia, M; Bellodi, L; Brambilla, F; Diaferia, G; Panerai, A; Perna, G; Petraglia, F; Sacerdote, P; Sciuto, G, 1992) |
| "Sixty patients with agoraphobia with panic attacks or panic disorder who completed a 4-month combined drug and behavioral group treatment program and were discharged on a regimen of alprazolam were interviewed 1." | 3.67 | Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. ( Charney, DS; Krystal, JH; Nagy, LM; Woods, SW, 1989) |
| "Two patients treated with alprazolam for panic disorder and agoraphobia developed a manic episode." | 3.67 | Alprazolam-induced manic episode in two patients with panic disorder. ( Fleury, D; Pecknold, JC, 1986) |
| "The anxiolytic triazolobenzodiazepine alprazolam was administered to six male patients, aged 26 to 46 years, with panic disorder or agoraphobia (with panic attacks) to assess clinical effects and steady-state pharmacokinetics following multiple dosing at three levels: 3." | 3.67 | Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. ( Barnhill, JG; Boxenbaum, HG; Ciraulo, DA; Greenblatt, DJ; Smith, RB, 1986) |
| " A decrease in therapeutic effects of alprazolam after an initial good response is described in three patients suffering from panic disorder with agoraphobia." | 3.67 | Fading of therapeutic effects of alprazolam in agoraphobia. Case reports. ( Fava, GA, 1988) |
| " To assess whether alprazolam alters noradrenergic function, the effects of alprazolam on baseline plasma free 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), and yohimbine-induced increases in plasma MHPG level, anxiety-nervousness, blood pressure, and somatic symptoms were studied in 14 patients with agoraphobia and panic disorder." | 3.67 | Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. ( Charney, DS; Heninger, GR, 1985) |
| "Clonazepam, a high-potency benzodiazepine marketed for the treatment of minor motor epilepsy, was used to treat 50 patients with panic disorder (N = 22) or agoraphobia with panic attacks (N = 28)." | 3.67 | Treatment of panic disorder and agoraphobia with clonazepam. ( Rosenbaum, JF; Spier, SA; Tesar, GE; Woods, SW, 1986) |
| "Ten cases are presented--two in detail--in which clonazepam was used successfully in patients with treatment-resistant panic disorder with or without agoraphobia." | 3.67 | Successful use of clonazepam in patients with treatment-resistant panic disorder. ( Rosenbaum, JF; Tesar, GE, 1986) |
| "Panic disorder is a chronic illness with only some degree of spontaneous recovery." | 2.67 | Discontinuation reactions to alprazolam in panic disorder. ( Pecknold, JC, 1993) |
| "Alprazolam is a widely used antianxiety agent, yet relatively little is known about the relationship between chronic oral doses and steady-state plasma levels." | 2.67 | The relationship of alprazolam dose to steady-state plasma concentrations. ( Antal, EJ; Ciraulo, DA; Goldberg, DA; Greenblatt, DJ; Olson, DR; Phillips, JP; Rand, EH; Raskin, RB; Shader, RI; Smith, RB, 1990) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 2.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "The alprazolam effects were apparent by week 1; the imipramine effects by week 4." | 2.67 | Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. ( Agras, WS; Clark, D; Ehlers, A; Hayward, C; King, R; Maddock, R; Margraf, J; Roth, WT; Taylor, CB, 1990) |
| "Alprazolam was effective in reducing panic and depressive symptomatology in both depressed and nondepressed subjects with panic disorder." | 2.66 | Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment. ( Burrows, GD; DuPont, RL; Lesser, IM; Lydiard, RB; Noyes, R; Pecknold, JC; Rifkin, A; Rubin, RT; Swinson, RP, 1988) |
| "Alprazolam treatment led to a complete remission of panic attacks in 85% of the patients; panics ceased within an average of 6 days, at a mean dose of 2." | 1.27 | Alprazolam treatment for panic disorders. ( Alexander, DD; Alexander, PE, 1986) |
| "Before treatment, IBQ hypochondriasis scores were similar to those of a group of hypochondriacal psychiatric patients." | 1.27 | Reduction in hypochondriasis with treatment of panic disorder. ( Clancy, J; Noyes, R; O'Gorman, TW; Reich, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (42.48) | 18.7374 |
| 1990's | 56 (49.56) | 18.2507 |
| 2000's | 7 (6.19) | 29.6817 |
| 2010's | 2 (1.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moylan, S | 1 |
| Staples, J | 1 |
| Ward, SA | 1 |
| Rogerson, J | 1 |
| Stein, DJ | 1 |
| Berk, M | 1 |
| Marazziti, D | 1 |
| Carlini, M | 1 |
| Dell'Osso, L | 1 |
| Starcevic, V | 2 |
| Kolar, D | 1 |
| Latas, M | 1 |
| Bogojevic, G | 1 |
| Kelin, K | 1 |
| Litvintsev, SV | 1 |
| Reznik, AM | 1 |
| Kvashnina, NV | 1 |
| Arbuzov, AL | 1 |
| Krylov, KE | 1 |
| Andersch, S | 1 |
| Hetta, J | 1 |
| Choi, YH | 1 |
| Vincelli, F | 1 |
| Riva, G | 1 |
| Wiederhold, BK | 1 |
| Lee, JH | 1 |
| Park, KH | 1 |
| Prasko, J | 1 |
| Houbová, P | 1 |
| Novák, T | 1 |
| Záleský, R | 1 |
| Espa-Cervená, K | 1 |
| Pasková, B | 1 |
| Vyskocilová, J | 1 |
| Uhlenhuth, EH | 2 |
| Leon, AC | 1 |
| Matuzas, W | 1 |
| Sheehan, DV | 5 |
| Sheehan, KH | 1 |
| Raj, BA | 1 |
| González, ER | 1 |
| Claycomb, JB | 1 |
| Coleman, JH | 2 |
| Greenblatt, DJ | 5 |
| Jones, KJ | 3 |
| Levine, PH | 2 |
| Orsulak, PJ | 1 |
| Peterson, M | 1 |
| Schildkraut, JJ | 1 |
| Uzogara, E | 1 |
| Watkins, D | 1 |
| Mark, SL | 1 |
| Ballenger, JC | 8 |
| O'Sullivan, GH | 1 |
| Noshirvani, H | 6 |
| Başoğlu, M | 10 |
| Marks, IM | 8 |
| Swinson, R | 2 |
| Kuch, K | 5 |
| Kirby, M | 2 |
| Brambilla, F | 4 |
| Perna, G | 4 |
| Garberi, A | 1 |
| Nobile, P | 2 |
| Bellodi, L | 4 |
| Arancio, C | 1 |
| Curran, HV | 3 |
| Bond, A | 1 |
| O'Sullivan, G | 5 |
| Bruce, M | 1 |
| Marks, I | 3 |
| Lelliot, P | 1 |
| Shine, P | 2 |
| Lader, M | 1 |
| Klein, DF | 3 |
| Swinson, RP | 11 |
| Kiliç, C | 4 |
| Brewin, CR | 1 |
| Lelliott, PT | 1 |
| McNamee, G | 1 |
| Sengun, S | 2 |
| Spiegel, DA | 1 |
| Roth, M | 2 |
| Weissman, M | 1 |
| Lavori, P | 2 |
| Gorman, J | 1 |
| Rush, J | 1 |
| Ballenger, J | 1 |
| Curtis, GC | 2 |
| Massana, J | 1 |
| Udina, C | 1 |
| Ayuso, JL | 1 |
| Cassano, GB | 2 |
| Perugi, G | 1 |
| Pecknold, JC | 7 |
| Lepola, UM | 1 |
| Rimón, RH | 1 |
| Riekkinen, PJ | 1 |
| Harmatz, JS | 1 |
| Shader, RI | 2 |
| Schweizer, E | 3 |
| Rickels, K | 3 |
| Weiss, S | 1 |
| Zavodnick, S | 1 |
| Shelton, RC | 1 |
| Harvey, DS | 1 |
| Stewart, PM | 1 |
| Loosen, PT | 1 |
| Fava, GA | 2 |
| Shioiri, T | 1 |
| Fujii, K | 1 |
| Someya, T | 1 |
| Takahashi, S | 1 |
| Bond, AJ | 1 |
| Bruce, MS | 1 |
| Pols, H | 1 |
| Verburg, K | 1 |
| Hauzer, R | 1 |
| Meijer, J | 1 |
| Griez, E | 1 |
| Rosenbaum, JF | 6 |
| Pollack, MH | 3 |
| Pollock, RA | 1 |
| Abelson, JL | 1 |
| Gold, PW | 1 |
| Raj, AB | 1 |
| Harnett-Sheehan, K | 1 |
| Dorotheo, J | 1 |
| Sheehan, MF | 1 |
| Trehan, R | 1 |
| Knapp, E | 1 |
| Swiontek, A | 1 |
| Coleman, B | 1 |
| Livanou, M | 1 |
| Klerman, GL | 3 |
| Battaglia, M | 1 |
| Sciuto, G | 1 |
| Diaferia, G | 1 |
| Petraglia, F | 1 |
| Panerai, A | 1 |
| Sacerdote, P | 1 |
| Lesser, IM | 3 |
| Lydiard, RB | 4 |
| Antal, E | 1 |
| Rubin, RT | 4 |
| DuPont, R | 2 |
| Cox, BJ | 2 |
| Endler, NS | 2 |
| Lee, PS | 1 |
| Albus, M | 2 |
| Zahn, TP | 1 |
| Breier, A | 1 |
| Toni, C | 1 |
| Musetti, L | 1 |
| Laraia, M | 1 |
| Ravaris, CL | 1 |
| Friedman, MJ | 1 |
| Hauri, PJ | 1 |
| McHugo, GJ | 1 |
| Maier, W | 3 |
| Roth, SM | 1 |
| Argyle, N | 3 |
| Buller, R | 3 |
| Brandon, S | 2 |
| Benkert, O | 2 |
| Rosenberg, R | 2 |
| Hooper, JF | 1 |
| Solyom, C | 1 |
| Solyom, L | 1 |
| Zarate, R | 1 |
| Craske, MG | 1 |
| Barlow, DH | 1 |
| Wincor, MZ | 1 |
| Munjack, DJ | 2 |
| Palmer, R | 2 |
| Mattick, RP | 1 |
| Andrews, G | 1 |
| Hadzi-Pavlovic, D | 1 |
| Christensen, H | 1 |
| Pohl, R | 1 |
| Balon, R | 1 |
| Fox, I | 2 |
| Yeragani, VK | 1 |
| Taylor, CB | 1 |
| Hayward, C | 1 |
| King, R | 1 |
| Ehlers, A | 1 |
| Margraf, J | 1 |
| Maddock, R | 1 |
| Clark, D | 1 |
| Roth, WT | 1 |
| Agras, WS | 1 |
| Rifkin, A | 3 |
| Burrows, GD | 4 |
| Noyes, R | 10 |
| Dupont, RL | 3 |
| Lesser, I | 1 |
| Davidson, JR | 1 |
| Lecrubier, Y | 1 |
| Hippius, H | 1 |
| Lopez, AL | 1 |
| Kathol, RG | 1 |
| Ciraulo, DA | 2 |
| Antal, EJ | 1 |
| Smith, RB | 2 |
| Olson, DR | 1 |
| Goldberg, DA | 1 |
| Rand, EH | 1 |
| Raskin, RB | 1 |
| Phillips, JP | 1 |
| Lepola, U | 1 |
| Jolkkonen, J | 1 |
| Rimón, R | 1 |
| Riekkinen, P | 1 |
| Fava, M | 1 |
| MacLaughlin, RA | 1 |
| Tesar, GE | 4 |
| Cohen, LS | 1 |
| Hirsch, M | 1 |
| Pyke, RE | 3 |
| Greenberg, HS | 1 |
| Crocker, B | 1 |
| Cabe, D | 1 |
| Brown, R | 1 |
| Usigli, R | 1 |
| Zulueta, A | 1 |
| McManus, M | 1 |
| McDowell, D | 1 |
| Leonard, M | 1 |
| De Albuquerque, A | 1 |
| Cottraux, J | 1 |
| Gentil, V | 1 |
| Greist, J | 1 |
| Hand, I | 1 |
| Liberman, RL | 1 |
| Relvas, JS | 1 |
| Tobeña, A | 1 |
| Tyrer, P | 1 |
| Carek, DJ | 1 |
| Steele, JJ | 1 |
| Cornish-McTighe, D | 1 |
| Charney, DS | 4 |
| Woods, SW | 4 |
| Nagy, LM | 1 |
| Krystal, JH | 1 |
| Clancy, J | 3 |
| Coryell, WH | 1 |
| Crowe, RR | 1 |
| Chaudhry, DR | 1 |
| Domingo, DV | 1 |
| Heninger, GR | 3 |
| Coryell, W | 4 |
| Crowe, R | 1 |
| Chaudhry, D | 1 |
| Liebowitz, MR | 2 |
| Fyer, AJ | 3 |
| Gorman, JM | 2 |
| Campeas, R | 1 |
| Levin, A | 1 |
| Davies, SR | 1 |
| Goetz, D | 1 |
| Judd, FK | 1 |
| Norman, TR | 1 |
| Marriott, PF | 1 |
| Carr, DB | 1 |
| Surman, OS | 2 |
| Watkins, WD | 1 |
| Fleury, D | 1 |
| Barnhill, JG | 1 |
| Boxenbaum, HG | 1 |
| Alexander, PE | 1 |
| Alexander, DD | 1 |
| Hollister, LE | 1 |
| Rizley, R | 1 |
| Kahn, RJ | 1 |
| McNair, DM | 1 |
| Frankenthaler, LM | 1 |
| Mayerhoff, D | 1 |
| Vital-Herne, J | 1 |
| Lesser, M | 1 |
| Brenner, R | 1 |
| Dager, SR | 1 |
| Cowley, DS | 1 |
| Dunner, DL | 1 |
| Herman, JB | 1 |
| Sachs, GS | 1 |
| Case, G | 1 |
| Laraia, MT | 1 |
| Howell, EF | 1 |
| Kraus, M | 1 |
| Dillon, D | 1 |
| Cohen, BS | 1 |
| Williams, J | 1 |
| Strom, TB | 1 |
| Coleman, J | 1 |
| Goodman, WK | 1 |
| Rifkin, B | 1 |
| Kinch, M | 1 |
| Aiken, B | 1 |
| Quadrino, LM | 1 |
| Spier, SA | 1 |
| Reich, J | 2 |
| O'Gorman, TW | 2 |
12 reviews available for alprazolam and Agoraphobia
| Article | Year |
|---|---|
The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Humans; Panic Disorder; Psychiatric S | 2011 |
Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clomipramine; Cognit | 2012 |
Psychopharmacology of the anxiety disorders.
Topics: Adrenergic beta-Antagonists; Adult; Agoraphobia; Alprazolam; Antidepressive Agents, Tricyclic; Anxie | 1984 |
Clinical issues in the long-term treatment of panic disorder.
Topics: Age Factors; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Child; Cognitive B | 1996 |
Pharmacological and behavioural treatment of panic disorder.
Topics: Agoraphobia; Alprazolam; Humans; Panic Disorder | 1992 |
Efficacy of benzodiazepines in panic disorder and agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Humans; Panic | 1990 |
Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Depressive Disorder; Humans; Panic | 1990 |
A review of the psychopharmacology of panic disorder: individual differences and non specific factors.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Combined Modality Therapy; Humans; Imipramine; Panic; Ph | 1991 |
Treatment of panic and agoraphobia. An integrative review.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Bibliographies as Topic; Clinical Tria | 1990 |
Continuation treatment of panic disorder with high-potency benzodiazepines.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Benzodiazepines; Clonazepam; Humans; P | 1990 |
Pharmacotherapeutic considerations in anxiety disorders.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; B | 1986 |
Agoraphobia.
Topics: Agoraphobia; Alprazolam; Behavior Therapy; Humans; Imipramine; Phobic Disorders | 1988 |
65 trials available for alprazolam and Agoraphobia
| Article | Year |
|---|---|
A 15-year follow-up study of patients with panic disorder.
Topics: Activities of Daily Living; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Sec | 2003 |
Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anticonvulsants; Clonazepam; Cognitive Behavior | 2005 |
Influence of personality disorder on the treatment of panic disorder--comparison study.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality | 2005 |
Psychopathology of panic attacks in panic disorder.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Cognition; Humans; I | 2006 |
The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Biological Availability; Cross-Over Studies; De | 2007 |
Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; | 1984 |
Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Combined Modality Therapy; Desensitization, Psychologic; Dose-Respon | 1994 |
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Female; Growth Hormone; Growth Hormone-Releasing Hormone; | 1995 |
Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Female; Humans; Hydrocortisone; Male; Middle Aged; Panic | 1995 |
Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder.
Topics: Adult; Affect; Agoraphobia; Alprazolam; Arousal; Combined Modality Therapy; Desensitization, Psychol | 1994 |
Panic disorder with agoraphobia.
Topics: Agoraphobia; Alprazolam; Combined Modality Therapy; Desensitization, Psychologic; Humans; Panic Diso | 1993 |
Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure.
Topics: Adult; Agoraphobia; Alprazolam; Combined Modality Therapy; Depressive Disorder; Desensitization, Psy | 1994 |
Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Arousal; Combined Modality Therapy; Desensitizati | 1994 |
Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse.
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Combined Modality Therapy; Desensitization, Psychologic; Fe | 1994 |
Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Arousal; Combined Modality Therapy; Desensitizatio | 1993 |
Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Combined Modality Therapy; Desensitization, Psycho | 1993 |
Maintenance drug therapy of panic disorder.
Topics: Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imipramine; | 1993 |
Discontinuation reactions to alprazolam in panic disorder.
Topics: Agoraphobia; Alprazolam; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Adminis | 1993 |
Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; D | 1993 |
Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; D | 1993 |
Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Me | 1993 |
Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic | 1996 |
Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
Topics: Adult; Aggression; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Arousal; Competitive Behavior; Doub | 1995 |
Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Arousal; Carbon Dioxide; Cross-Over Studies; Do | 1996 |
Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial.
Topics: Agoraphobia; Alprazolam; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedul | 1997 |
Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Follow-Up Studies; Humans; Male; Memory | 1999 |
Drug treatment of panic disorder. Reply to comment by Marks and associates.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Cross-Cultural Comparison; Dose-Response Relationship, D | 1992 |
Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
Topics: Adult; Agoraphobia; Alprazolam; Clinical Protocols; Dose-Response Relationship, Drug; Double-Blind M | 1992 |
Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures.
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Female; Galvanic Skin Response; Heart Rate; Humans; Hydroco | 1992 |
Treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Panic Disorde | 1992 |
A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Arousal; Dose-Response Relationship, Drug; Double- | 1992 |
A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1991 |
Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Double-Blind Method; Fear; Female; Humans; Imipramine; Male | 1991 |
Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Depressive Disorder; Double-Blind Method; Female; | 1991 |
The structure of phobias in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; | 1991 |
Efficacy of benzodiazepines in panic disorder and agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Humans; Panic | 1990 |
Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Depressive Disorder; Humans; Panic | 1990 |
Alprazolam levels and response in panic disorder: preliminary results.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Chromatography, Gas; Female; Humans; | 1991 |
Treatment of panic and agoraphobia. An integrative review.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Bibliographies as Topic; Clinical Tria | 1990 |
Lorazepam vs. alprazolam in the treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Fear; Female; Humans; Lorazepam; Male; Mental D | 1990 |
Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial.
Topics: Adult; Agoraphobia; Alprazolam; Analysis of Variance; Anxiety; Anxiety Disorders; Depression; Disabi | 1990 |
Sequence of improvement in agoraphobia with panic attacks.
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Double-Blind Method; Fear; Female; Follow-Up Studies; Human | 1990 |
Drug treatment of panic disorder: early response to treatment as a predictor of final outcome.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Arousal; Double-Blind Method; Female; Humans; Imi | 1990 |
Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Benzodiazepines; Depression; Diazepam; Fear; Female; Humans; Hydroco | 1990 |
The relationship of alprazolam dose to steady-state plasma concentrations.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Dose-Response Relations | 1990 |
Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; beta-Endorphin; Clinical Trials as Topic; Double- | 1989 |
Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clinical Trials as Topic; Clonazepam; Dehydroepiandrosterone; Double | 1989 |
Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Arousal; Benzodiazepines | 1989 |
Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Clinical Trials as Topic; Double-Blind Method; Fear; Fem | 1989 |
The 'efficacy' of alprazolam in panic disorder and agoraphobia: a critique of recent reports.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Double-Blind Method; Fear; Hum | 1989 |
Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Double-Blind Method; Fear; Humans; Lorazepam; Panic; Ran | 1989 |
Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Depressive Disorder; Dexametha | 1985 |
Alprazolam in the treatment of panic disorders.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Clinical Tr | 1986 |
Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; | 1986 |
A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Clinical Trials as To | 1986 |
Placebo response in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Dexamethasone; Diazepam | 1988 |
HPA axis disturbance and treatment outcome in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clinical Trials as Topic; Dexamethasone; Fear; Female; Humans; Hydro | 1988 |
Lorazepam vs. alprazolam in the treatment of panic disorder.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Fear; Female; Humans; Lorazepam; Male; Mental Disorders; | 1988 |
Overview of the Cross-National Collaborative Panic Study.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Fear; Goals; Humans; Imipramin | 1988 |
Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Do | 1988 |
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Ataxia; Chemical and Drug Induced Liver Injury; F | 1988 |
Immunological response to stress in agoraphobia and panic attacks.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Clinical Trials as Topic; Fear; | 1986 |
Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Fear; Humans; Imipramine; Pani | 1986 |
Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Dose-Response Relationship, Drug; Fear; Humans; Panic; P | 1987 |
Taper withdrawal studies with alprazolam in patients with panic disorder and agoraphobia.
Topics: Adult; Agoraphobia; Alprazolam; Benzodiazepines; Fear; Female; Humans; Male; Panic; Phobic Disorders | 1986 |
39 other studies available for alprazolam and Agoraphobia
| Article | Year |
|---|---|
Panic disorder patients at the time of air strikes.
Topics: Adult; Agoraphobia; Aircraft; Alprazolam; Catchment Area, Health; Clonazepam; Female; Follow-Up Stud | 2002 |
[Clinical picture and treatment of agoraphobia with panic disorder].
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Humans; Middle Aged; Military | 2003 |
Panic disorder may respond to new 'antidepressants'.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Fear; Female; Huma | 1982 |
Endogenous anxiety: implications for nosology and treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Female; Gal | 1983 |
Agoraphobia and panic disorder: treatment with alprazolam.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Fear; Female | 1984 |
Alprazolam in panic disorder: a retrospective analysis.
Topics: Adult; Agoraphobia; Alprazolam; Depressive Disorder; Female; Humans; Male; Panic Disorder; Psychiatr | 1993 |
Anxiety sensitivity.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Cognitive Behavioral Therapy; Combined | 1996 |
Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment.
Topics: Adrenocorticotropic Hormone; Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Arousal; Corticotr | 1997 |
Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Delayed-Ac | 1996 |
Personality dimensions in panic disorder before and after effective treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Humans; Male; Middle Aged; Panic Disord | 1996 |
Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Follow-Up Studies; Humans; Male; Panic | 1997 |
Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Humans; Male; Middle Aged; Panic Disord | 1999 |
Psychoimmunoendocrine aspects of panic disorder.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Agoraphobia; Alprazolam; beta-Endorphin; Corticotrop | 1992 |
A prospective study of panic and anxiety in agoraphobia with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Arousal; Combined Modality Therapy; Desensitizati | 1992 |
A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
Topics: Agoraphobia; Alprazolam; Female; Humans; Imipramine; Male; Panic Disorder; Psychiatric Status Rating | 1992 |
House calls and alprazolam for agoraphobia.
Topics: Agoraphobia; Alprazolam; Double-Blind Method; House Calls; Humans | 1991 |
Situational exposure treatment versus panic control treatment for agoraphobia. A case study.
Topics: Adaptation, Psychological; Adult; Agoraphobia; Alprazolam; Arousal; Behavior Therapy; Combined Modal | 1990 |
Switching patients from alprazolam to clonazepam.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clonazepam; Dose-Response Relationship, Drug; Drug Admin | 1990 |
Three cases of panic disorder with agoraphobia in children.
Topics: Adolescent; Agoraphobia; Alprazolam; Child; Fear; Female; Humans; Imipramine; Male; Panic; Phobic Di | 1989 |
Depression in panic disorder and response to alprazolam therapy.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Depressive Disorder; Fear; Humans; Panic; Psychiatric St | 1989 |
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Behavior Therapy; Combined Modality Therapy; Depr | 1989 |
A withdrawal syndrome after abrupt discontinuation of alprazolam.
Topics: Adult; Agoraphobia; Akathisia, Drug-Induced; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Ben | 1985 |
Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Blood Press | 1985 |
A case of alprazolam-related hepatitis.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Chemical an | 1986 |
Alprazolam-induced manic episode in two patients with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Bipolar Dis | 1986 |
Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder.
Topics: Administration, Oral; Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Dose-Res | 1986 |
Alprazolam treatment for panic disorders.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Fear; Femal | 1986 |
Alprazolam-induced manic reaction.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder | 1986 |
Biological markers in panic states: lactate-induced panic and mitral valve prolapse.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Creatinine | 1987 |
Clonazepam in the treatment of panic disorder and agoraphobia.
Topics: Adult; Aged; Agoraphobia; Alprazolam; Carbon Dioxide; Clonazepam; Fear; Female; Humans; Male; Middle | 1987 |
Alprazolam in the treatment of social phobia.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Female; Humans; Male; Middle Aged; Panic; Phobic | 1988 |
Alprazolam in the treatment of panic attack patients with and without major depression.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Depressive Disorder; Fear; Female; Humans; Male; | 1988 |
Fading of therapeutic effects of alprazolam in agoraphobia. Case reports.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Female; Follow-Up Stud | 1988 |
Antipanic drug effects during lactate infusion in lactate-refractory panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Desipramine; Fear; Female; Fluoxetine; Humans; Imipramine | 1987 |
Agoraphobia.
Topics: Agoraphobia; Alprazolam; Anxiety, Separation; Behavior Therapy; Combined Modality Therapy; Humans; I | 1987 |
Treatment of panic disorder and agoraphobia with clonazepam.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepino | 1986 |
The effect of state anxiety on personality measurement.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety; Anxiety Disorders; Benzodiazepines; Female; Humans; Male; P | 1986 |
Successful use of clonazepam in patients with treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clonazepam; D | 1986 |
Reduction in hypochondriasis with treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Fear; Humans; Hypochondriasis; Panic; Phobic Disorders; Sick Role | 1986 |